EMEA-000527-PIP01-08

Key facts

Invented name
Lucentis
Active substance
ranibizumab
Therapeutic area
Ophthalmology
Decision number
P/183/2009
PIP number
EMEA-000527-PIP01-08
Pharmaceutical form(s)
  • Solution for injection – single-use vial
  • Solution for injection – single-use pre-filled syringe
Condition(s) / indication(s)
  • Visual impairment due to macular edema associated with branch retinal vein occlusion
  • Visual impairment due to macular edema associated with central retinal vein occlusion
  • Visual impairment due to diabetic macular edema
Route(s) of administration
Intravitreal use
Contact for public enquiries
Applicant: Novartis Europharm Limited

E-mail: paediatric.enquiries@novartis.com
Phone: +41 61 324 1111
 

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating